MD I. de Weerdt publications

foto

Publications MD I. de Weerdt

Position
PhD Candidate
Main activities
Research
Specialisation
T cell-based therapy in chronic lymphocytic leukemia
Focus of research

T-cell based treatment strategies for chronic lymphocytic leukemia

2019

  • de Weerdt Iris, Kater Aron P. Combining novel agents in chronic lymphocytic leukemia: Greater than the sum of its parts? HemaSphere 2019;3 (S2):44-46
  • Hofland Tom, de Weerdt Iris, ter Burg Hanneke, de Boer Renate, Tannheimer Stacey, Tonino Sanne H., Kater Arnon P., Eldering Eric Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes Journal of immunology (Baltimore, Md. 2019;203 (8):2100-2109 [PubMed]
  • de Weerdt Iris, Hofland Tom, de Boer Renate, Dobber Johan A., Dubois Julie, van Nieuwenhuize Denise, Mobasher Mehrdad, de Boer Fransien, Hoogendoorn Mels, Velders Gerjo A., van der Klift Marjolein, Remmerswaal Ester B. M., Bemelman Frederike J., Niemann Carsten U., Kersting Sabina, Levin Mark-David, Eldering Eric, Tonino Sanne H., Kater Arnon P. Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment Blood advances 2019;3 (17):2642-2652 [PubMed]
  • de Weerdt I., Hofland T., Lameris R. Erratum: De Weerdt I, Hofland T, Lameris R, et al. Improving CLL Vg9Vd2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib (Blood. 2018 132:21 (2260-2272) DOI: 10.1182/blood-2017-12-822569) Blood 2019;134 (15):1271-1272 [PubMed]
  • Hofland Tom, Endstra Sanne, Gomes Calum K P, de Boer Renate, de Weerdt Iris, Bobkov Vladimir, Riedl Jurgen A, Heukers Raimond, Smit Martine J, Eldering Eric, Levin Mark-David, Kater Arnon P, Tonino Sanne H Natural Killer Cell Hypo-responsiveness in Chronic Lymphocytic Leukemia can be Circumvented In Vitro by Adequate Activating Signaling HemaSphere 2019;3 (6):e308 [PubMed]

2018

  • de Weerdt Iris, Hofland Tom, Lameris Roeland, Endstra Sanne, Jongejan Aldo, Moerland Perry D., de Bruin Renee C. G., Remmerswaal Ester B. M., ten Berge Ineke J. M., Liu Nora, van der Stelt Mario, Faber Laura M., Levin Mark-David, Eldering Eric, Tonino Sanne H., de Gruijl Tanja D., van der Vliet Hans J., Kater Arnon P. Improving CLL Vγ9Vδ2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib Blood 2018;132 (21):2260-2272 [PubMed]

2017

  • de Weerdt Iris, Koopmans Suzanne M., Kater Arnon P., van Gelder Michel Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach Haematologica 2017;102 (10):1629-1639 [PubMed]

2016

  • de Weerdt Iris, van Hoeven Vera, Munneke J. Marius, Endstra Sanne, Hofland Tom, Hazenberg Mette D., Kater Arnon P. Innate lymphoid cells are expanded and functionally altered in chronic lymphocytic leukemia Haematologica 2016;101 (11):e461-e464 [PubMed]

2013

  • de Weerdt Iris, Eldering Eric, van Oers Marinus H., Kater Arnon P. The biological rationale and clinical efficacy of inhibition of signaling kinases in chronic lymphocytic leukemia Leukemia research 2013;37 (7):838-847 [PubMed]